CARY, N.C.--(BUSINESS WIRE)--THREAD, a leading technology and service provider enabling decentralized clinical trials (DCTs), announced today that it has been awarded Frost & Sullivan’s 2021 Customer Value Leadership Award in the decentralized clinical trials industry. The award recognizes THREAD’s innovation; growth; and comprehensive customer-oriented offerings. Frost & Sullivan’s global team of analysts independently evaluated criteria across the areas of business and customer impact to determine award recipients.
“THREAD’s innovations via its decentralized trials platform are sure to progress the industry to a hybrid system between a decentralized and centralized service model,” said Ojaswi Rana, Frost & Sullivan Best Practices research analyst. “Further, the company transforms participants’ previously costly, tedious, and cumbersome clinical trial process into a safe, trustworthy, responsive, hassle-free, convenient, and inexpensive health care experience.”
Historically, participant recruitment, data collection and analysis, patient adherence, coordination across trial sites, and logistical challenges have caused critical delays in clinical trials. THREAD provides a singular, fully configurable, and comprehensive DCT technology platform that allows pharmaceutical and contract research organizations (CROs) to plan and perform clinical trials virtually. THREAD’s platform enables faster patient recruitment and broader diversity in trials by expanding the access radius around study sites worldwide. THREAD’s expertise and proprietary technology have benefited clients in other important areas, including the following:
- Enhanced data quality through continuous, real-world data capture
- A more convenient and streamlined participant and stakeholder experience to enable increased engagement
- Faster recruitment of study participants
- Global scalability through a compliant and secure platform available worldwide
“THREAD has continued to grow its leadership position by innovating and creating new products and solutions that serve an ever-evolving need in the clinical trial industry. THREAD’s recognition signifies an even greater accomplishment, transforming the face of clinical development and supporting hundreds of studies with hundreds of thousands of participants available in over 50 countries,” added Rana.
“The COVID-19 pandemic further highlighted the urgent need for modernization and innovation in the clinical trials market, proving traditional clinical trial models and practices ineffective and unsustainable,” said THREAD CEO John Reites. “We are thrilled with this recognition from Frost & Sullivan for our advancements in the planning and execution of decentralized clinical trials.”
For more information on the Frost & Sullivan 2021 Customer Value Leadership Award, click here.
THREAD is a leading provider of a proprietary, decentralized research platform and suite of supporting services used by biopharma, CROs and life science organizations to remotely capture data from participants and sites during, in-between and in lieu of in-clinic visits. THREAD's platform and supporting services are helping customers to shorten study launch timelines, reduce study budgets with Virtual Visits, and bring studies from the clinic to patients' homes. THREAD provides key platform features such as eConsent, eCOA/ePRO, sensors, reminders, and telehealth virtual visits to support remote data capture, hybrid virtual studies, and fully decentralized studies in key therapeutic areas. In 2019, THREAD was acquired by strategic health care investors Water Street Healthcare Partners and JLL Partners. Visit www.THREADresearch.com to learn more.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.